Peptide injections: why peptides are injected, and what the trials report about it

Almost every therapeutic peptide is injected, because the digestive system treats a swallowed peptide the same way it treats the protein in a steak. This guide covers why that is, which routes studies have used, and where the real risks sit.

Published September 14, 2026

This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.

Why the shot exists

Peptides are made of the same material as the protein in food, and the digestive system is very good at taking that material apart. Enzymes in the stomach and small intestine cut peptide bonds, and the gut wall is a poor gateway for what is left. Swallow an unmodified peptide and most of it never reaches the bloodstream intact.

Injection bypasses that. A subcutaneous injection places the drug in the fat layer under the skin, where it is absorbed into circulation over hours. Combine that with molecular engineering that slows clearance, such as attaching a fatty acid chain so the peptide binds to albumin and circulates for days, and a hormone that would normally last minutes becomes a once-weekly injection. That combination is why semaglutide and tirzepatide are weekly rather than hourly.

The routes studies have used

Subcutaneous

This is the route in the large trials. STEP 1 gave once-weekly subcutaneous semaglutide at 2.4 mg to 1,961 adults for 68 weeks. SURMOUNT-1 gave once-weekly subcutaneous tirzepatide at 5, 10 or 15 mg to 2,539 adults for 72 weeks, with a 20-week escalation period built in. When people talk about "peptide injections" in a weight-management context, this is nearly always what they mean.

Intramuscular

Into muscle rather than fat, with a longer needle. Absorption is generally faster. It is used for some products and procedures but is not the route of the weekly incretin trials.

Intra-articular and other local routes

Some research has placed peptides directly at a target site. A 2021 retrospective chart review at a single Florida clinic described intra-articular BPC 157 injection for knee pain in sixteen contacted patients, of whom twelve had received BPC 157 alone. It was uncontrolled, follow-up varied, and no standardized instrument measured function or quality of life. It is a useful example of what a clinic-level report looks like, and of how far that is from a randomized trial.

Intravenous

Infusion into a vein, used in research settings under supervision. A 2025 pilot infused BPC-157 intravenously in two adults and reported no measurable effect on tested biomarkers of heart, liver, kidney, thyroid or blood glucose, and no side effects. Two participants over three days is a safety signal of the smallest possible size, and the authors said further study was needed.

What the trials recorded about tolerability

For the incretin peptides, the adverse events that dominated the trials were digestive rather than related to the needle. In STEP 1, nausea and diarrhea were the most common adverse events with semaglutide, typically transient and mild to moderate in severity, and subsided with time; 4.5 percent of the semaglutide group discontinued treatment because of gastrointestinal events, against 0.8 percent of the placebo group. Both phase 3 obesity trials used long dose-escalation periods, which is part of why those figures look as they do.

For compounds without trials of that size, there is no comparable tolerability dataset. Absence of reported side effects in a twelve-person uncontrolled pilot is not evidence of safety; it is evidence that twelve people were asked.

Where the real risk sits

• Arithmetic. Unit confusion on an insulin syringe is the most common way a small intended amount becomes a large delivered one. See the units converter and the reconstitution calculator.
• Sterility. Anything injected has to be sterile. The reconstitution guide covers why the diluent, the vial stopper and the storage time matter.
• Product identity. A vial sold as research material carries no pharmacy assurance of what is in it or how much. That is a different risk category from a prescription filled by a licensed pharmacy.
• No prescriber. Self-directed use means no one is checking interactions, contra- indications or what the symptom actually is.

Questions worth asking a clinic

• Who is the prescriber, what is their licence, and will I speak with them?
• Is the product FDA-approved, or compounded? If compounded, by which licensed pharmacy?
• What does the published evidence for this compound consist of, and in what species?
• What is the total cost over a year, including consultations and any labs?
• What happens if I stop, and what does the plan look like then?

Our cost guide covers the pricing side, and the directory lists clinics by city.

Frequently asked questions